Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone orin combination with a half-sized secretory leukocyte protease inhibitor orthe nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice

Authors
Sano, C Shimizu, T Sato, K Kawauchi, H Kawahara, S Tomioka, H
Citation
C. Sano et al., Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone orin combination with a half-sized secretory leukocyte protease inhibitor orthe nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice, ANTIM AG CH, 43(2), 1999, pp. 360-364
Citations number
34
Categorie Soggetti
Microbiology
Journal title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
ISSN journal
00664804 → ACNP
Volume
43
Issue
2
Year of publication
1999
Pages
360 - 364
Database
ISI
SICI code
0066-4804(199902)43:2<360:TEOBKA>2.0.ZU;2-R
Abstract
The effects of half-sized secretory leukocyte protease inhibitor or diclofe nac sodium administered alone or in combination with the benzoxazinorifamyc in KRM-1648 on the therapeutic eificacy of KRM-1648 against Mycobacterium a vium complex (MAC) in mice were studied. Neither of the two anti-inflammato ry drugs affected the efficacy of KRM-1648, while they exerted significant modulating effects on tumor necrosis factor alpha production by MAC-infecte d macrophages.